TOP HEADLINES

Featured Story

  • Sanofi digs into details on hastened Zika effort

    Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.

Duke, NIAID track HIV evolution with eyes on creating a vaccine

A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.

South Korea's Green Cross to supply Americas with flu vaccine in $32M deal

South Korea's Green Cross announced a $32 million deal on Wednesday to supply its flu vaccines to the Pan American Health Organization, the WHO's regional office in the Americas.

U.S. Army, GSK's P. vivax malaria vaccine fails to protect in early trial

A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.

New South Korean study could help direct MERS vaccine development

Several players are working on vaccines for Middle East respiratory syndrome (MERS), including the NIH and tandem GeneOne and Inovio, both of which had successful animal trials for their candidates. Now, a new study out of South Korea--showing that the MERS virus mutated during the outbreak--could help vaccine developers pinpoint their target on the surface of the MERS virus.

Novavax explores Zika vaccine R&D effort as virus continues to spread

Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.

MORE NEWS

From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaAsia
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • FiercePharmaMarketing
  • FierceAnimalHealth
  • More Fierce Network sites
FierceBiotech
Tiny Celator surges on promising cancer data and preps an FDA submission

Celator Pharmaceuticals saw its shares roughly quintuple in value on Monday afternoon after the biotech posted positive Phase III results for its nano-powered blood cancer therapy, putting the tiny company in line for an FDA filing this year.

FierceMedicalDevices
Philips readies for mid- to high-single-digit HealthTech growth with reorg, lighting disposal

Philips is slated to report with a reorganized business structure that better reflects its HealthTech priorities for the first time on with its first quarter earnings due at the end of April. Philips' CEO Frans van Houten said that he's looking for mid-to-high single digit growth from each of the three new segments: Connected Care & Health Informatics; Diagnosis & Treatment; and Personal Health.